The effect of clinically recommended Evolut sizes on anchorage forces after BASILICA.


Journal

Journal of biomechanics
ISSN: 1873-2380
Titre abrégé: J Biomech
Pays: United States
ID NLM: 0157375

Informations de publication

Date de publication:
30 03 2021
Historique:
received: 30 12 2020
accepted: 16 01 2021
pubmed: 19 2 2021
medline: 28 5 2021
entrez: 18 2 2021
Statut: ppublish

Résumé

Coronary artery obstruction (CAO), a fatal complication of transcatheter aortic valve replacement (TAVR), is commonly found after Valve-in-Valve implantation inside a degenerated bioprosthetic valve. Leaflet laceration (BASILICA technique) has been proposed to prevent CAO and to potentially reduce the risk of leaflet thrombosis. We have previously demonstrated that this technique can reduce the anchorage forces of the TAVR device, which may lead to future complications. In this short communication, we hypothesize that the anchorage force reduction can be minimized by implanting a TAVR with a larger diameter, if two sizes are clinically recommended. We evaluated this hypothesis by employing finite element models of the deployments of the Evolut 26 and 29 mm inside a 27 mm Mitroflow valve, with and without leaflet lacerations. The results show that a laceration substantially decreases the contact area between the Evolut stent and the Mitroflow valve. The larger Evolut has a larger contact area and stronger anchorage forces. Additionally, the anchorage forces are less sensitive to additional lacerations in the larger Evolut (29 case). The results suggest that a larger self-expending device can ensure stronger anchorage and can lower the risk of possible migration, when TAVR is performed in a lacerated bioprosthesis.

Identifiants

pubmed: 33601185
pii: S0021-9290(21)00083-X
doi: 10.1016/j.jbiomech.2021.110303
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

110303

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Prof. Finkelstein serves as a proctor, advisor and speaker for Medtronic Inc. and for Edwards Lifesciences. The remaining authors have no conflict of interest to declare.

Auteurs

Halit Yaakobovich (H)

Department of Biomedical Engineering, Tel Aviv University, Tel Aviv, Israel.

Romina Plitman Mayo (R)

School of Mechanical Engineering, Tel Aviv University, Tel Aviv, Israel.

Uri Zaretsky (U)

Department of Biomedical Engineering, Tel Aviv University, Tel Aviv, Israel.

Ariel Finkelstein (A)

Division of Cardiology, Tel Aviv Medical Center, Tel Aviv, Israel.

Dar Weiss (D)

Department of Biomedical Engineering, Tel Aviv University, Tel Aviv, Israel; Department of Biomedical Engineering, Yale University, CT, USA.

Gil Marom (G)

School of Mechanical Engineering, Tel Aviv University, Tel Aviv, Israel. Electronic address: maromgil@tau.ac.il.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH